Esperion Therapeutics, Ann Arbor, Mi

Description

• Esperion Therapeutics, Inc. is the lipid management company passionately committed to developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated LDL-C. Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced lipid management team at Esperion is committed to developing new LDL-C lowering therapies that will make a substantial impact on reducing global CVD; the leading cause of death around the world. Bempedoic acid, the Company's lead product candidate, is a targeted therapy that significantly reduces elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. Phase 1 and 2 studies conducted previously in more than 800 patients treated with bempedoic acid have produced clinically relevant LDL-C lowering results of up to 30 percent as monotherapy, approximately 50 percent in combination with ezetimibe, and an incremental 20+ percent when added to stable statin therapy. The Company has two Phase 3 products in development: 1) bempedoic acid (monotherapy) an oral, once-daily pill, and 2) an, oral, once-daily fixed dose combination pill of bempedoic acid and ezetimibe (BA+EZ).For more information, please visit www.esperion.com.
• 

  Headquarters:3891 Rancheron Drive Suite 150, Ann Arbor, Michigan, United States

  More
• 

  Phone Number: +1 734-887-3903

• 

  Website: https://www.esperion.com

• 

  Employees:450

• 

  Revenue:$100 - 250M

• 

  Legal Name:Esperion Therapeutics, Ann Arbor, Mi

• Esperion Therapeutics, Ann Arbor, Mi's Social Media

  
• Is this data correct?

• |  NAICS Code: 541714  |

  Show More